中国循证医学杂志

中国循证医学杂志

Survivin mRNA 表达与卵巢癌相关性的 Meta 分析

查看全文

目的 系统评价卵巢癌组织中 Survivin mRNA 表达与卵巢癌的相关性。 方法 计算机检索 PubMed、The Cochrane Library(2016 年 11 期)、CBM、CNKI、VIP 和 WanFang Data 数据库,搜集公开发表的所有关于 Survivin mRNA 表达与卵巢癌临床病理特征关系的病例-对照研究,检索时限均为从建库至 2016 年 11 月。由 2 位评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用 RevMan 5.2 软件进行 Meta 分析。 结果 共纳入 10 个病例-对照研究。Meta 分析结果显示:Survivin mRNA 表达在卵巢癌组高于对照组[OR=24.63,95% CI(13.44,45.15),P<0.000 01],其在低分化组表达高于高分化组[OR=3.69,95% CI(2.29,5.93),P<0.000 01],在临床 Ⅲ~Ⅳ 期组表达高于临床 Ⅰ~Ⅱ 期组[OR=4.76,95% CI(2.99,7.57),P<0.000 01]。但其表达与有无淋巴结转移、有无腹水及组织类型无关。 结论 Survivin mRNA 表达与卵巢癌具有相关性。受纳入研究数量和质量限制,上述结论需进一步开展高质量研究加以验证。

Objective To systematically review the relationship between the expression of Survivin mRNA and ovarian cancer. Methods PubMed, The Cochrane Library (Issue 11, 2016), CBM, CNKI, VIP and WanFang Data databases were searched to identify case-control studies concerning the association between the expression of Survivin mRNA and ovarian cancer up to November 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 10 studies were included. The positive of Survivin mRNA in ovarian cancer group was significantly higher than that in control group (OR=24.63, 95% CI 13.44 to 45.15,P<0.000 01). The positive of Survivin in low differentiated group was significantly higher than that in high differentiation group (OR=3.69, 95% CI 2.29 to 5.93,P<0.000 01). The positive of Survivin in clinical stage of Ⅲ-Ⅳ was significantly higher than that in clinical stage of Ⅰ-Ⅱ (OR=4.76, 95% CI 2.99 to 7.57,P<0.000 01), respectively. However, the expression of Survivin mRNA was not associated with lymph node metastasis, ascites and histological type. Conclusion The current evidence indicates that the expression of Survivin mRNA is significantly correlated with ovarian cancer and its clinicopathologic features. Due to the limited quantity and quality of includes studies, the above conclusions are needed to be verified by more high quality studies.

关键词: Survivin; 卵巢肿瘤; Meta 分析; 系统评价; 病例-对照研究

Key words: Survivin; Ovarian neoplasms; Meta-analysis; Systematic review; Case-control study

引用本文: 许英艺, 张雅雅, 林智才, 陈玉强. Survivin mRNA 表达与卵巢癌相关性的 Meta 分析. 中国循证医学杂志, 2017, 17(3): 320-326. doi: 10.7507/1672-2531.201611081 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Basu P, De P, Mandal S, et al. Study of pattern of care of ovarian cancer patients in specialized cancer institute in Kolkata, Eastern India. Indian J Cancer, 2009, 46(1): 28-33.
3. Modepalli N, Venugopal SB. Clinicopathological study of surface epithelial tumours of the ovary: an isntitutional study. J Clin Diagn Res, 2016, 10(10): EC01-EC04.
4. 李克红, 张若曦, 张英杰, 等. 凋亡抑制基因 Survivin 在卵巢癌组织中的表达及其临床意义. 中国实用医刊, 2012, 39(8): 4-6.
5. 史惠蓉, 兰莉, 乔玉环, 等. 卵巢癌组织中 Survivin 和 PCNA 的表达. 郑州大学学报(医学版), 2004, 39(4): 552-554.
6. 宋和存, 向征, 李慧. Survivin Ki67 在卵巢原发癌与转移癌中的表达及其临床意义. 中国实用妇科与产科杂志, 2006, 22(3): 201-203.
7. 王言奎, 杨锦芝, 罗兵, 等. 上皮性卵巢癌中 Survivin 的表达及意义. 中国妇产科临床杂志, 2003, 4(5): 368-372.
8. 杨锦芝, 赵冬梅. 凋亡抑制基因 Survivin 在上皮性卵巢癌中的表达及其意义. 滨州医学院学报, 2003, 26(4): 243-244.
9. Li GZ, Pei SL, Hong LM, et al. Survivin expression in ovarian cancer. Exp Oncol, 2007, 29(2): 121-125.
10. 张淑兰, 赵长清, 林蓓, 等. 凋亡抑制基因 survivin 在卵巢上皮性癌组织中的表达及其与 bcl-2、bax 蛋白表达的关系. 中华妇产科杂志, 2003, 38(4): 203-206.
11. 张树荣, 杨淑莉, 李荷莲. 卵巢癌组织中 MDR1、Survivin、TopoⅡβ 的表达及临床意义. 中国妇幼健康研究, 2006, 17(6): 464-466.
12. 张意茗, 张向宁. XIAP、survivin、LPA 及 CA125 在上皮性卵巢癌中的表达. 山东大学学报(医学版), 2007, 45(3): 317-321.
13. 赵杨, 张颐, 温放. 凋亡抑制蛋白和耐药因子在卵巢癌中的表达及与化疗的关系. 解剖科学进展, 2007, 13(2): 111-114, 118.
14. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the qualityof nonrandomized studies in meta-analysis. Available at: .
15. 许英艺, 张雅雅, 卢伟锋, 等. 骨桥蛋白表达与中国人肝癌及临床病理特征关系的 Meta 分析. 中国循证医学杂志, 14(12): 1418-1423.
16. Ambrosini G, Adida C, Sirugo G, et al. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem, 1998, 273(18): 11177-11182.
17. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human a survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 2001, 40(4): 1117-1123.
18. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibtitor, Survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest, 1999, 79(9): 1121-1126.
19. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol, 1999, 113(6): 1076-1081.
20. Nasu S, Yangihashi A, Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res, 2002, 22(3): 1839-1843.
21. Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA, 2001, 285(3): 324-328.
22. Ambrosini G, Adjda C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphma. Nat Med, 1997, 3(8): 917-921.
23. Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated gene bax and bcl-2 in ovarian cancer. Anticancer Res, 1997, 17(3C): 2233-2240.